NLRP3 and metabolic dysfunction-associated steatotic liver disease: Emerging evidence has indicated that NLRP3 inflammasome activation is implicated in metabolic syndrome, obesity, and NAFLD (Szabo and Csak, 2012; Lee et al., 2013; Esser et al., 2014).